A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

Hiroshi Mukae; Hiroshi Yotsuyanagi; Norio Ohmagari; Yohei Doi; Takumi Imamura; Takuhiro Sonoyama; Takahiro Fukuhara; Genki Ichihashi; Takao Sanaki; Keiko Baba; Yosuke Takeda; Yuko Tsuge; Takeki Uehara

bioRxiv (2022) - Comments
doi: 10.1101/2022.05.17.22275027

Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Takahiro Fukuhara, Genki Ichihashi, Takao Sanaki, Keiko Baba, Yosuke Takeda, Yuko Tsuge, Takeki Uehara